Medtronic (MDT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Medtronic reported revenue of $8.96 billion for the quarter ended October 2025, reflecting a year-over-year increase of 6.6% and surpassing the Zacks Consensus Estimate of $8.86 billion by 1.11% [1] - The company's EPS for the quarter was $1.36, up from $1.26 in the same quarter last year, exceeding the consensus estimate of $1.31 by 3.82% [1] Revenue Breakdown - U.S. Revenue: $4.52 billion, slightly below the average estimate of $4.53 billion, with a year-over-year increase of 4.9% [4] - International Revenue: $4.45 billion, exceeding the average estimate of $4.33 billion [4] - Cardiovascular - Structural Heart & Aortic: $566 million, above the estimate of $548.63 million, with a 15% year-over-year increase [4] - Cardiovascular - Cardiac Rhythm & Heart Failure: $905 million, surpassing the estimate of $866.81 million [4] - Worldwide Cardiovascular Revenue: $3.44 billion, exceeding the estimate of $3.37 billion, with a 10.8% year-over-year increase [4] - Worldwide Diabetes Revenue: $757 million, above the estimate of $749.91 million, with a 10.4% year-over-year increase [4] - Worldwide Medical Surgical Revenue: $2.17 billion, below the average estimate of $2.37 billion, with a 2% year-over-year increase [4] - Worldwide Neuroscience Revenue: $2.56 billion, exceeding the estimate of $2.49 billion, with a 4.5% year-over-year increase [4] - Neuroscience - Neuromodulation: $520 million, above the estimate of $510.92 million, with an 8.3% year-over-year increase [4] - Neuroscience - Cranial & Spinal Technologies: $1.3 billion, matching the estimate, with a 5.3% year-over-year increase [4] - Cardiovascular - Coronary & Peripheral Vascular: $655 million, slightly below the estimate of $663.24 million, with a 1.9% year-over-year increase [4] Stock Performance - Medtronic's shares have returned +0.4% over the past month, outperforming the Zacks S&P 500 composite's +0.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]